Palbociclib shows improved PFS but not improved OS for ER+ HER2- mBC patients

Bookmark and Share
Published: 19 Jul 2022
Views: 174
Dr Bishal Gyawali - Queen's University, Kingston, Canada

Dr Bishal Gyawali speaks to ecancer about the negative results of the PALOMA-2 OS trial.

PAL was the first cyclin-dependent kinase 4/6 (CDK4/6) inhibitor approved for ER+/HER2– ABC based on the randomized, phase 2 PALOMA-1 study.

The results of the PALOMA-2 found that cross-line endocrine therapy did not improve overall survival.

The control arm exceeded expectations. The overall survival was 51 months thus meaning the overall improvement in treatments, diagnosis and history of the disease.